In this review I examine the clinical uses of psychedelics as an adjunct to psychotherapy to treat three major mental health disorders; Major Depressive Disorder (MDD), Post Traumatic Stress Disorder (PTSD) and Addiction (Substance Use Disorder). I assess the hallucinogen treatment model's efficacy in treating chronic mental health disorders that have been unresponsive to legal and traditional psychiatric treatment. I review the earlier studies conducted with psychedelics and discuss the more recent ones. This review may be helpful to therapists and clinicians who would like to further their understanding of psychedelic therapy.

Mental illnesses, especially depression, are a global problem that require new treatment options to those whose symptoms are resistant to the current ones. Psilocybin, which is a naturally occurring drug in mushrooms, has become a potential candidate. It affects the brain by deactivating certain areas, causing not only changes in perception and consciousness but antidepressive responses as well, thereby improving well-being. Previous studies have looked at psilocybin and how it affects the brain, and also shown that short trials with psilocybin can cause long-lasting improvement. Here, I conducted an analysis including nine experimental articles that had studied psilocybin’s effects on depressive symptoms. Results confirm that psilocybin does decrease depressive symptoms, even long-lastingly, while only transient mild side effects being fairly common. Some conclusions could also be drawn of which types of patients will benefit of psilocybin treatment most likely. Future research with bigger sample sizes is needed, as well as more focus on identifying the ideal settings and patients of psilocybin-assisted therapy. / Mental ohälsa och särskilt depression är globala problem. Nya behandlingsalternativ behövs för de som inte får hjälp av nuvarande behandlingar. Psilocybin är ett ämne som finns i så kallade magiska svampar och har blivit en potentiell kandidat. Psilocybin påverkar hjärnan genom att inaktivera vissa delar, vilket leder till förändringar i perception, medvetandet och antidepressiva responser bland annat. Tidigare forskning har fokuserat på hur psilocybin påverkar hjärnan samt visat att även kortvarig behandling med psilocybin kan framkalla en långvarig förbättring av hur man mår. Denna analys inkluderar nio experiementella studier om psilocybins effekter på depressiva symtom. Resultatet visar att psilocybin minskar depressiva symptom, även långvarigt. Endast kortvariga milda bieffekter var rapporterade. Framtida forskning bör ha ett större antal av deltagare samt fokusera på att identifiera idealgruppen för denna typ av behandling.

Recently, psychedelic science (PS) has been going through a resurge with a vast increase in publications. Psychedelic-Assisted Therapy (PAT) is demonstrating promising results across the treatment of various psychiatric disorders; however, psychedelic science remains absent from the curriculum of both medical and psychology students in Sweden. This study examined medical students' attitudes towards PS, comparing them with psychology students' attitudes, which were previously investigated. The medical students' knowledge and attitudes towards psychedelic science and its therapeutic potential were analysed using a cross-sectional survey study design. Data from psychology students were collected in the spring of 2023, while data from medical students were collected in the fall of 2023. Both datasets were based on a digital survey, Attitudes on Psychedelics Questionnaire, APQ. Multiple Mann-Whitney U tests and a chi-square test were performed across the two groups. n = 316 psychology students and n = 709 medical students answered the survey. Psychology students held more positive attitudes, rated themself as more knowledgeable and followed new findings about psychedelic science to a higher degree compared to medical students. There were no differences between the groups concerning the interests in learning about psychedelics as part of their curriculum, nor the current amount of education in PS they have received. Students who have used psychedelics themselves for recreational purposes held more positive attitudes compared to non-users. This study revealed an unmet request for education about PS from students. We argue this lack of education in PS may delay a future potential implementation of PAT in Sweden.

Psychiatry is in a crisis. Mental health disorders are on the rise worldwide and there are currently not enough efficient treatment methods that would meet the patients’ needs. Hence, the societal and economic costs of mental health problems are enormous, as well as the suffering of individuals afflicted by mental health problems. Lysergic acid diethylamide (LSD) and psilocybin are substances that create an altered state of consciousness characterized by altered sensory perception and on some occasions, ego-dissolution, and mystical experiences. In recent studies, LSD and psilocybin have been shown to carry significant therapeutic potential in the treatment of depression and anxiety disorders in conjunction with psychotherapy. The therapeutic effects of LSD and psilocybin have also been shown to persist for between 3-12 months post-treatment. LSD and psilocybin, like other classical hallucinogens, increase serotonin availability, which has been suggested to attenuate symptoms of anxiety and depression. In addition, LSD and psilocybin alter the activity of the default mode network, which has been suggested to be overly active in depressed and anxious patients. This essay is a literature review of the neural mechanisms of LSD and psilocybin, their potential therapeutic effects in the treatment of depressive and anxiety disorders, and how insights about said neural mechanisms may be useful in understanding the possible application of psychedelics in the treatment of depressive and anxiety disorders. In sum, recent studies have provided converging and convincing evidence on therapeutic potential of LSD and psilocybin. Yet, few conclusions on the exact neural mechanisms of how LSD and psilocybin alleviate depressive and anxiety symptoms can be made. Although the future of this research field looks promising, archaic national- and international regulations continue to be a hindrance to research into psychedelic drugs. Yet, due to the psychiatric crisis and the promising results so far, more studies in this field are warranted.

Background: A recent surge in interest for psychedelic-assisted therapy has manifested itself in exponential increases of subject-related academic publications as well as broad media attention. However, a lot is still to be wished for regarding the question of how the therapy actually works. Objective: To map the current empirical literature regarding “mechanisms of change” and corresponding relevant measures of these mechanisms. Method: The present essay is a scoping review. The process involves systematically acquiring relevant literature by conducting a literature search on two different platforms, Pubmed and PsychInfo, in order to extract and map the data seen as relevant to the research question. Results: Putative “mechanisms of change” and associated measures are successfully mapped and presented in a chart as well as in a basic qualitative content-analysis. The content analysis presents three separate categories used to conceptualize different mechanisms of change: Acute subjective experience, psychological flexibility and neural flexibility. Conclusion: Psychedelic-assisted therapy involves a number of complex mechanisms of change which can be studied both from a psychological as well as neurobiological perspective. These mechanisms can be thought to be dependent on processes in the acute subjective experience and consist in the form of increased psychological flexibility. Relevant measures include psychometric instruments that can be well complemented by FMRI-data. In order to gain a better understanding of these processes regarding the way they relate to one another, what moderates their outcome on depressive symptoms and how clinical application is optimized, further research is warranted. / SammanfattningBakgrund: Ett förhöjt intresse för psykedelisk assisterad terapi har på senare tid visat sig i exponentiella ökningar av ämnesrelaterade akademiska publikationer såväl som bred medieuppmärksamhet. Det finns emellertid mycket att önska när det kommer till frågan om hur terapin faktiskt fungerar. Syfte: Att kartlägga den aktuella empiriska litteraturen angående förmodade ”förändringsmekanismer” och motsvarande relevanta mått på dessa mekanismer. Metod: Föreliggande uppsats är en omfattningsgranskning (scoping review). Processen inbergrep systematisk inhämtning av relevant litteratur genom att genomföra litteratursökningar på två olika plattformar, Pubmed och PsychInfo, för att sedan extrahera och kartlägga den data som ansågs relevant för forskningsfrågan. Resultat: Förmodade "förändringsmekanismer" och tillhörande mått kartläggs framgångsrikt och presenteras i såväl tabell som i en grundläggande kvalitativ innehållsanalys. Innehållsanalysen presenterar tre separata kategorier som används för att konceptualisera olika förmodade förändringsmekanismer: Akut subjektiv upplevelse, psykologisk flexibilitet och neural flexibilitet. Slutsats: Psykedelisk assisterad terapi involverar ett antal komplexa förmodade förändringsmekanismer som kan studeras både ur ett psykologiskt såväl som neurobiologiskt perspektiv. Relevanta mått inkluderar psykometriska instrument som väl kan kompletteras med FMRI-data. För att få en bättre förståelse för dessa processer när det gäller hur de förhåller sig till varandra, vad som dämpar deras resultat vid depressiva symtom och hur klinisk tillämpning optimeras, är ytterligare forskning motiverad.